FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other…
The U.S. Food and Drug Administration approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients (12 years of age and older and weighing at least 35…
Read More...
Read More...
